Drug Research
Recursion Pharmaceuticals Raises $13M To Discover New Drugs Using Artificial Intelligence
Recursion Pharmaceuticals announced its $12.9 million Series A round of funding, led by leading deep technology investor Lux Capital, with participation from Obvious Ventures, Epic Ventures, Data Collective, AME Cloud Ventures, Wild Basin Investments, and several prominent angel investors....
Drug Research
Bayer and DelSiTech Partner to Develop Innovative Drug Delivery Technology for Ophthalmology
Bayer and DelSiTech Ltd , a Finnish drug delivery technology and drug development company, have signed a Collaboration and Technology Licence Agreement for the worldwide application of DelSiTech’s Silica Matrix drug delivery platform to a number of Bayer’s compounds...
Drug Research
Amgen And Arrowhead Pharmaceuticals Announce Two Cardiovascular Collaborations
Amgen and Arrowhead Pharmaceuticals Inc announced two license and collaboration agreements to develop and commercialize RNA interference (RNAi) therapies for cardiovascular disease. These are the first programs to utilize Arrowhead's proprietary subcutaneous RNAi delivery platform. RNAi...
Drug Research
Boehringer Ingelheim boosts immune-oncology pipeline through collaboration with viratherapeutics
Boehringer Ingelheim and ViraTherapeutics announced a long term collaboration to jointly develop a next generation oncolytic virus therapy platform and to investigate Vira Therapeutic’s lead candidate VSV-GP (Vesicular Stomatitis Virus (VSV) glycoprotein (GP)) alone and in combination with other...
Drug Research
Catalent Showcases Advanced Formulations, Development Technologies And Drug Delivery Solutions At CPhI Worldwide
Catalent Pharma Solutions (Booth 3J16), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products announced a full agenda for the upcoming CPhI Worldwide Conference and Exhibition, to be held at...
Drug Research
Bayer and Forschungszentrum Juelich agree on research collaboration
At the signing ceremony of the new research collaboration: Back row from left: Dr. Simone Gatzke, Forschungszentrum Juelich, Raphael Dumain, Dr. Isolde Häuser-Hahn and Dr. habil Guenter Welz from Bayer, Prof. Ulrich Schurr, Juelich, Dr. Samir Bennabi, Bayer. ...
Drug Research
GSK presents positive results from phase III FULFIL study at ERS International Congress
GlaxoSmithKline plc and Innoviva, Inc announced the presentation of further data from the pivotal phase III FULFIL study with investigational closed triple combination therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI 100/62.5/25 mcg). in patients with chronic obstructive pulmonary disease...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
